☆ 4.7 Article

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy

LEUKEMIA (2023)

Related references

Note: Only part of the references are listed.

Article Endocrinology & Metabolism

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy

Anne M. A. Tryggestad et al.

Summary: This study aimed to reduce the risk of biochemical relapse in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy by administering personalized dendritic cell vaccines as adjuvant therapy. The results showed promising efficacy of the vaccine in reducing biochemical relapse incidence, as well as associations between baseline immune response and vaccine response during the vaccination period. Further investigation in larger cohorts is warranted to validate these findings and explore the potential of dendritic cell vaccines in post-surgical treatment of high-risk prostate cancer.

PROSTATE (2022)

Add to Collection

Review Oncology

Research progress on dendritic cell vaccines in cancer immunotherapy

Jifeng Yu et al.

Summary: DC vaccines have shown promising results in the treatment of hematological malignancies, including AML and MDS. Different strategies have been explored, such as using mo-DCs and DCleu as the main types of DCs, and loading DCs with various cancer-related molecules to enhance efficacy. Additionally, combination with conventional chemotherapy, specific antibodies, and immune checkpoint-targeting therapies have been investigated to improve the outcomes of DC vaccination. Overall, significant progress has been made in the field of DC vaccine immunotherapy.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Oncology

Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia

Ashley Tabah et al.

Summary: This study compared the efficacy of oral and injectable azacitidine in the maintenance therapy of acute myeloid leukemia. The results showed that oral azacitidine was associated with significantly improved overall survival. This has important clinical implications for the maintenance therapy of older patients with AML.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

Add to Collection

Review Medicine, General & Internal

The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia

Davide Lazzarotto et al.

Summary: Monitoring Minimal Residual Disease (MRD) is crucial in acute myeloid leukemia (AML) for guiding treatment, determining the need for stem cell transplantation, and detecting relapse early. However, more than 50% of AML patients lack specific molecular markers for MRD monitoring. This review focuses on the use of WT1 overexpression as an MRD marker in AML patients undergoing intensive chemotherapy, including stem cell transplantation. The standardized method of European LeukemiaNet is recommended for achieving optimal sensitivity and specificity.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Hematology

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy

Bhagirathbhai Dholaria et al.

Summary: This evidence-based review examines the role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) and recommends the preferential use of allogeneic HCT with myeloablative conditioning in eligible patients. Allogeneic HCT offers a survival benefit in intermediate- and high-risk AML patients and is now considered part of standard clinical care.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Hematology

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Premal D. Lulla et al.

Summary: Leukemia-specific T cells (mLSTs) selectively recognized and killed leukemia antigen-pulsed cells in vitro, showing no activity against recipient's normal cells. Infusions of mLSTs were well tolerated with no severe GVHD, leading to antileukemia effects and promising outcomes for AML/MDS patients after HCT.

BLOOD (2021)

Add to Collection

Review Hematology

AML and the art of remission maintenance

Marcos de Lima et al.

Summary: Relapse in AML is common, and there is no standard maintenance therapy. Ongoing studies are evaluating various therapeutic options, and new strategies are needed to identify patients who will benefit the most.

BLOOD REVIEWS (2021)

Add to Collection

Review Oncology

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Christian M. Vonk et al.

Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.

CANCERS (2021)

Add to Collection

Article Oncology

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

Tobias Herold et al.

LEUKEMIA (2020)

Add to Collection

Article Medicine, General & Internal

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

A. H. Wei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Immunology

Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses

Adarsh Kumbhari et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial

Felix S. Lichtenegger et al.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia

Heleen H. Van Acker et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection

Review Oncology

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Ghaneya Al-Khadairi et al.

CANCERS (2019)

Add to Collection

Article Hematology

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Gerwin Huls et al.

BLOOD (2019)

Add to Collection

Article Biochemistry & Molecular Biology

WT1 influences apoptosis and proliferation of immature mice granular cells through regulation of the wnt/β-catenin signal pathway

Juan Wang et al.

CELLULAR AND MOLECULAR BIOLOGY (2019)

Add to Collection

Article Hematology

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Sebastien Anguille et al.

BLOOD (2017)

Add to Collection

Article Oncology

Immune Responses and Long-Term Disease Recurrence Status After Telomerase-Based Dendritic Cell Immunotherapy in Patients With Acute Myeloid Leukemia

Hanna J. Khoury et al.

CANCER (2017)

Add to Collection

Review Oncology

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia

Marion Subklewe et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)

Add to Collection

Article Hematology

Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression

Sarah Pozzi et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Add to Collection

Article Oncology

Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy

Willemijn van den Ancker et al.

ONCOIMMUNOLOGY (2013)

Add to Collection

Article Oncology

PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

Avital L. Amir et al.

CLINICAL CANCER RESEARCH (2011)

Add to Collection

Article Oncology

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease

YaZhen Qin et al.

LEUKEMIA RESEARCH (2009)

Add to Collection

Article Oncology

The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis

N. Hosen et al.

LEUKEMIA (2007)

Add to Collection

Article Medicine, Research & Experimental

Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70

Anke Zobywalski et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2007)

Add to Collection

Article Biochemistry & Molecular Biology

The human tumor antigen repressor of retinoic acid PRAME is a dominant receptor signaling

MT Epping et al.

CELL (2005)

Add to Collection

Article Biochemistry & Molecular Biology

Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1

EUH Sim et al.

ONCOGENE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.